DDInter624 DDInter904
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Idarubicin
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Efavirenz {u} (Compound) causes {v} (Side Effect) Cardiac failure congestive
Cardiac failure congestive {u} (Side Effect) is caused by {v} (Compound) Idarubicin
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idarubicin
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Efavirenz {u} (Compound) causes {v} (Side Effect) Cardiac failure congestive
Cardiac failure congestive {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Efavirenz {u} (Compound) causes {v} (Side Effect) Rash generalised
Rash generalised {u} (Side Effect) is caused by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Idarubicin (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Idarubicin (Compound)
Efavirenz (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Idarubicin (Compound)
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Doxorubicin (Compound) and Doxorubicin (Compound) resembles Idarubicin (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Doxorubicin (Compound) and Doxorubicin (Compound) resembles Idarubicin (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Doxorubicin (Compound) and Doxorubicin (Compound) resembles Idarubicin (Compound)
Efavirenz (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Doxorubicin (Compound) and Doxorubicin (Compound) resembles Idarubicin (Compound)
Efavirenz (Compound) causes Rash generalised (Side Effect) and Rash generalised (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin